PFIZER, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.64 USD | +1.11% |
|
+4.52% | +2.74% |
| 02:22pm | Pfizer: article on Lyme vaccine in The Lancet | CF |
| 12:25pm | Pfizer Partners with Abu Dhabi to Advance Research on Sickle Cell Disease | MT |
ETFs positioned on Pfizer, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.74% | 254 M€ | +13.33% | - | |
| 9.37% | 17 M€ | +7.01% | - | |
| 3.49% | 9 M€ | -.--% | - | |
| 2.99% | 23 M€ | +14.66% | - | |
| 2.80% | 2 M€ | -.--% | - | |
| 2.70% | 5 M€ | -72.95% | - | |
| 2.45% | 562 M€ | -0.69% | ||
| 2.13% | 2 M€ | +9.08% | ||
| 1.97% | 0 M€ | -.--% | ||
| 1.50% | 24 M€ | -0.63% | - | |
| 1.50% | 26 M€ | -0.44% | - | |
| 1.50% | 224 M€ | +2.90% | - | |
| 1.48% | 1 M€ | +2.21% | - | |
| 1.48% | 8 M€ | -.--% | ||
| 1.40% | 9 M€ | -4.31% | - | |
| 1.24% | 13,519 M€ | +3.16% | ||
| 1.07% | 375 M€ | +7.92% | ||
| 1.04% | 800 M€ | +4.84% | ||
| 1.00% | 26 M€ | +22.35% | - | |
| 0.98% | 0 M€ | 0.00% | - | |
| 0.90% | 6 M€ | +17.98% | - |
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
Pharmaceuticals
Calendar
2024-06-10
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
29.31
USD
Average target price
31.92
USD
Spread / Average Target
+8.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.81% | 166B | |
| +42.60% | 748B | |
| +33.82% | 598B | |
| -5.74% | 356B | |
| +17.79% | 325B | |
| +3.37% | 283B | |
| +17.23% | 245B | |
| +9.43% | 211B | |
| -3.80% | 209B | |
| +6.74% | 165B |
- Stock Market
- Equities
- PFE Stock
- Funds and ETFs Pfizer, Inc.
